Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.

Importance: High-intensity statin is strongly recommended in patients at very high risk (VHR) of atherosclerotic cardiovascular disease (ASCVD). However, concerns about statin-associated adverse effects result in underuse of this strategy in practice.

Objective: To evaluate the outcomes of a moderate-intensity statin with ezetimibe combination in VHR and non-VHR patients with ASCVD.

A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.

Objectives: We compared 4-year efficacy and safety of sirolimus-eluting stents (SES) and paclitaxel-eluting stents (PES) in patients with diabetes mellitus (DM).

Background: Four-year comparison of SES with PES in diabetic patients has not been evaluated in a randomized manner.

Methods: This prospective, multicenter, randomized study compared SES (n = 200) and PES (n = 200) implantation in diabetic patients.

Aspirin non-responsiveness in Korean subjects on dual anti-platelet treatment determined by two different platelet function assays.

Several techniques are available for measuring platelet function during aspirin therapy, but none is well standardized, and the reported incidence of aspirin non-responders varies widely, from 5 to 50%. We evaluated the optical platelet aggregation test and the Platelet Function Analyzer-100 test (PFA-100) for assessing aspirin responsiveness in patients receiving dual anti-platelet therapy, and we measured the incidence of non-responders to aspirin among Koreans. The study enrolled 88 participants including 51 patients on dual anti-platelet therapy, 31 controls, and 6 other volunteers.

Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial.

Objective: The aim of this study was to compare effectiveness of the Sirolimus- (SES) and Paclitaxel-eluting stent (PES) in primary angioplasty for acute ST-elevation myocardial infarction (STEMI).

Background: It has been reported that SES and PES have been more effective than bare-metal stents in reducing restenosis and cardiac events in a broad range of patients with coronary artery disease. However, it is unknown whether there may be differences between these two drug-eluting stents in terms of efficacy in the setting of acute STEMI.

Application of albumin-adjusted ischemia modified albumin index as an early screening marker for acute coronary syndrome.

Background: Existing cardiac markers are not sensitive for reversible myocardial ischemia. Ischemia modified albumin (IMA) has recently been shown to be an early and sensitive marker of myocardial ischemia. We established a newly standardized, albumin-adjusted IMA index that was more sensitive and accurate than the conventional IMA value.

The incidence and clinical impact of stent strut fractures developed after drug-eluting stent implantation.

Background: Cases of stent strut fractures (SSFs) after DES implantation have been reported, but the clinical significance is uncertain. Then we sought to define the incidence and clinical implications of SSFs developed after drug-eluting stent (DES) implantation.

Methods: We gathered SSF cases from 13 centers in Korea retrospectively.